Ascentage Pharma Unveils Promising Preclinical Combination Therapy Data at AACR 2026

Ascentage Pharma Group International (HKEX: 6855) announced the presentation of four highly promising preclinical studies at the American Association for Cancer Research (AACR) 2026 Annual Meeting held in San Diego, California. These studies highlight the company’s strategic focus on developing innovative combination therapies which address significant unmet needs in oncology, potentially impacting future clinical pipelines and shareholder value.

Key Highlights of the Announcement

• Four preclinical posters presented at AACR 2026 Annual Meeting, featuring three proprietary drug candidates:
  • Olverembatinib (HQP1351): a novel BCR-ABL inhibitor
  • APG-2449: a FAK/ALK/ROS1 triple tyrosine kinase inhibitor
  • APG-5918: a PRC2/EED inhibitor
• Expansion of Olverembatinib’s potential use beyond its current approval in China for chronic myeloid leukemia (CML) into other cancers such as endometrial carcinoma and mantle cell lymphoma, including combination approaches with BTK inhibitors.
• Combination strategies targeting resistance mechanisms in difficult-to-treat cancers, including BRAF-mutant tumors (with APG-2449) and small-cell lung cancer (with APG-5918).
• Preclinical data to inform future clinical development and complement ongoing global registrational trials.

Detailed Study Summaries

1. Olverembatinib in Endometrial Carcinoma (EC)

• Background: EC is the most common gynecologic malignancy in developed countries, with limited treatment options for advanced or recurrent cases.
• Olverembatinib’s Mechanism: Targets multiple kinases important in cancer progression.
• Key Findings:
  • Olverembatinib demonstrated robust antitumor efficacy in a variety of preclinical EC models, both in vitro and in vivo.
  • When combined with standard chemotherapy, it showed synergistic effects, enhancing apoptosis and suppressing critical oncogenic signaling pathways (FGFR2, PI3K/AKT, MEK/ERK).
  • Supports future clinical trials for Olverembatinib in EC, alone or in combination therapy.

2. Olverembatinib + BTK Inhibitor in Mantle Cell Lymphoma (MCL)

• Background: MCL is an aggressive, rare non-Hodgkin lymphoma. BTK inhibitors have improved outcomes but monotherapy responses are limited.
• Combination Rationale: Dual inhibition of Lyn and BTK may enhance efficacy.
• Key Findings:
  • Olverembatinib, alone and in combination with BTK inhibitor acalabrutinib, potently inhibited MCL cell proliferation and induced apoptosis and cell cycle arrest in preclinical models.
  • The combination showed superior tumor suppression and downregulated NF-kB activity, suggesting a strong mechanistic rationale for clinical investigation of this combination in MCL.

3. APG-2449 in BRAF V600E-Mutant Tumors (Colorectal Cancer & Melanoma)

• Background: BRAF V600E mutations drive cancer progression in several tumors. Resistance to current BRAF/MEK inhibitor therapies is common, often due to compensatory signaling.
• Key Findings:
  • APG-2449, which targets FAK and other kinases, showed selective sensitivity in BRAF V600E-mutant cancer cell lines.
  • APG-2449 suppressed resistance mechanisms and synergistically enhanced the efficacy of dabrafenib (BRAF inhibitor) + trametinib (MEK inhibitor) in preclinical models.
  • Supports clinical development of APG-2449 in combination regimens for melanoma and colorectal cancer patients harboring BRAF V600E mutations.

4. APG-5918 (EED Inhibitor) in Small-Cell Lung Cancer (SCLC)

• Background: SCLC rapidly develops resistance to chemotherapy, with poor prognosis.
• Mechanistic Insight: PRC2-mediated repression of SLFN11 contributes to resistance. APG-5918 disrupts PRC2, potentially reversing this effect.
• Key Findings:
  • Combination of APG-5918 and topoisomerase I inhibitors (topotecan, irinotecan) synergistically inhibited proliferation and induced apoptosis in preclinical SCLC models.
  • In vivo, APG-5918 + irinotecan showed strong antitumor activity without significant toxicity.
  • APG-5918 increased expression of chemosensitivity markers (SLFN11, p21) and enhanced DNA damage/apoptotic signaling, supporting its role as a chemosensitizer.
  • Findings warrant clinical studies evaluating APG-5918 combined with DNA-damaging agents in SCLC.

Implications for Shareholders and Potential Share Price Impact

• Expansion into New Indications: The data supports broadening Ascentage’s pipeline beyond current approvals, which may drive future growth and market opportunities.
• Combination Strategies: Addressing resistance mechanisms in hard-to-treat cancers positions Ascentage as a leader in next-generation oncology therapeutics.
• Potential Price Sensitivity: Positive preclinical data, if translated into clinical success, could significantly enhance the company’s valuation and attractiveness to investors and partners.
• Ongoing Risk: Caution is warranted as the company notes that it may not ultimately be able to develop and market APG-5918 (Pelcitoclax) and APG-2449 successfully. Clinical development carries inherent risks, and there is no assurance of regulatory approval or market adoption.

Board and Leadership Update

The announcement was authorized by Dr. Yang Dajun, Chairman and Executive Director. The Board consists of experienced professionals in the biotech and pharmaceutical sectors, including both executive and independent non-executive directors.

Disclaimer: The information provided is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. Drug development is subject to significant risks, and preclinical data may not always predict clinical success. Investors should assess all risks and consult with professional advisors before making investment decisions.

View ASCENTAGE-B Historical chart here